{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:49:22Z","timestamp":1790866162030,"version":"4.1.0"},"reference-count":45,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK108868"],"award-info":[{"award-number":["DK108868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK032083"],"award-info":[{"award-number":["DK032083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK110845"],"award-info":[{"award-number":["DK110845"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK085509"],"award-info":[{"award-number":["DK085509"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK104223"],"award-info":[{"award-number":["DK104223"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["AI110503"],"award-info":[{"award-number":["AI110503"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:p>Very recently one of the largest type 1 diabetes prevention trials using daily administration of oral insulin or placebo was completed. After 9 years of study enrollment and follow-up, the randomized controlled trial failed to delay the onset of clinical type 1 diabetes, which was the primary end point. The unfortunate outcome follows the previous large-scale trial, the Diabetes Prevention Trial\u2013Type 1 (DPT-1), which again failed to delay diabetes onset with oral insulin or low-dose subcutaneous insulin injections in a randomized controlled trial with relatives at risk for type 1 diabetes. These sobering results raise the important question, \u201cWhere does the type 1 diabetes prevention field move next?\u201d In this Perspective, we advocate for a paradigm shift in which smaller mechanistic trials are conducted to define immune mechanisms and potentially identify treatment responders. The stage is set for these interventions in individuals at risk for type 1 diabetes as Type 1 Diabetes TrialNet has identified thousands of relatives with islet autoantibodies and general population screening for type 1 diabetes risk is under way. Mechanistic trials will allow for better trial design and patient selection based upon molecular markers prior to large randomized controlled trials, moving toward a personalized medicine approach for the prevention of type 1 diabetes.<\/jats:p>","DOI":"10.2337\/dbi17-0043","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T19:25:34Z","timestamp":1529695534000},"page":"1211-1215","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":15,"title":["Learning From Past Failures of Oral Insulin Trials"],"prefix":"10.2337","volume":"67","clinical-trial-number":[{"clinical-trial-number":"nct03396484","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-5244","authenticated-orcid":false,"given":"Aaron W.","family":"Michels","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"2022031300131475100_B1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/dc15-0101","article-title":"Predicting type 1 diabetes using biomarkers","volume":"38","author":"Bonifacio","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"key":"2022031300131475100_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2337\/db09-1378","article-title":"Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset","volume":"59","author":"Ferrannini","year":"2010","journal-title":"Diabetes"},{"key":"2022031300131475100_B4","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1210\/jc.2003-031887","article-title":"Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY)","volume":"89","author":"Barker","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300131475100_B5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2337\/diabetes.51.3.646","article-title":"Genetic risk determines the emergence of diabetes-associated autoantibodies in young children","volume":"51","author":"Kupila","year":"2002","journal-title":"Diabetes"},{"key":"2022031300131475100_B6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/diabetes.48.3.460","article-title":"Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study","volume":"48","author":"Ziegler","year":"1999","journal-title":"Diabetes"},{"key":"2022031300131475100_B7","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"key":"2022031300131475100_B8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc18-S002","article-title":"Sec. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00125-017-4384-2","article-title":"Understanding and preventing type 1 diabetes through the unique working model of TrialNet","volume":"60","author":"Battaglia","year":"2017","journal-title":"Diabetologia"},{"key":"2022031300131475100_B10","doi-asserted-by":"crossref","first-page":"e011144","DOI":"10.1136\/bmjopen-2016-011144","article-title":"Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study","volume":"6","author":"Raab","year":"2016","journal-title":"BMJ Open"},{"key":"2022031300131475100_B11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/pedi.12301","article-title":"Feasibility of screening for T1D and celiac disease in a pediatric clinic setting","volume":"17","author":"Gesualdo","year":"2016","journal-title":"Pediatr Diabetes"},{"key":"2022031300131475100_B12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MED.0b013e32834803ae","article-title":"2011 Update: antigen-specific therapy in type 1 diabetes","volume":"18","author":"Michels","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2022031300131475100_B13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2337\/dc15-0349","article-title":"Prevention and reversal of type 1 diabetes--past challenges and future opportunities","volume":"38","author":"Skyler","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa012350","article-title":"Effects of insulin in relatives of patients with type 1 diabetes mellitus","volume":"346","author":"Diabetes Prevention Trial--Type 1 Diabetes Study Group","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031300131475100_B15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B16","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"JAMA"},{"key":"2022031300131475100_B17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"key":"2022031300131475100_B18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaut.2016.03.008","article-title":"Strategies for clinical trials in type 1 diabetes","volume":"71","author":"Ehlers","year":"2016","journal-title":"J Autoimmun"},{"key":"2022031300131475100_B19","doi-asserted-by":"crossref","first-page":"e005559","DOI":"10.1136\/bmjopen-2014-005559","article-title":"Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial","volume":"4","author":"Waldron-Lynch","year":"2014","journal-title":"BMJ Open"},{"key":"2022031300131475100_B20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs \u03b2-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"2022031300131475100_B21","doi-asserted-by":"crossref","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"Todd","year":"2016","journal-title":"PLoS Med"},{"key":"2022031300131475100_B22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11892-016-0783-x","article-title":"Biomarkers of \u03b2-cell stress and death in type 1 diabetes","volume":"16","author":"Mirmira","year":"2016","journal-title":"Curr Diab Rep"},{"key":"2022031300131475100_B23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2337\/dc16-0360","article-title":"Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose","volume":"39","author":"Hao","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B24","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/db11-1538","article-title":"Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data","volume":"61","author":"Greenbaum","year":"2012","journal-title":"Diabetes"},{"key":"2022031300131475100_B25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00281-014-0438-4","article-title":"Insulitis in human type 1 diabetes: a comparison between patients and animal models","volume":"36","author":"In\u2019t Veld","year":"2014","journal-title":"Semin Immunopathol"},{"key":"2022031300131475100_B26","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.2337\/db15-1615","article-title":"differential insulitic profiles determine the extent of \u03b2-cell destruction and the age at onset of type 1 diabetes","volume":"65","author":"Leete","year":"2016","journal-title":"Diabetes"},{"key":"2022031300131475100_B27","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.2337\/db14-0365","article-title":"Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes","volume":"63","author":"Arif","year":"2014","journal-title":"Diabetes"},{"key":"2022031300131475100_B28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2337\/db16-1025","article-title":"Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes","volume":"66","author":"Michels","year":"2017","journal-title":"Diabetes"},{"key":"2022031300131475100_B29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11892-017-0915-y","article-title":"Deciphering the pathogenesis of human type 1 diabetes (T1D) by interrogating T cells from the \u201cscene of the crime\u201d","volume":"17","author":"Kent","year":"2017","journal-title":"Curr Diab Rep"},{"key":"2022031300131475100_B30","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/nm.4203","article-title":"Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes","volume":"22","author":"Babon","year":"2016","journal-title":"Nat Med"},{"key":"2022031300131475100_B31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db14-0858","article-title":"Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes","volume":"64","author":"Pathiraja","year":"2015","journal-title":"Diabetes"},{"key":"2022031300131475100_B32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2022031300131475100_B33"},{"key":"2022031300131475100_B34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/ng.3353","article-title":"Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk","volume":"47","author":"Hu","year":"2015","journal-title":"Nat Genet"},{"key":"2022031300131475100_B35","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.1100746","article-title":"Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation","volume":"187","author":"Michels","year":"2011","journal-title":"J Immunol"},{"key":"2022031300131475100_B36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1172\/JCI97739","article-title":"Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes","volume":"128","author":"Ostrov","year":"2018","journal-title":"J Clin Invest"},{"issue":"4","key":"2022031300131475100_B37","first-page":"CD003893","article-title":"Methyldopa for primary hypertension","author":"Mah","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031300131475100_B38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1196\/annals.1337.002","article-title":"Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop","volume":"1037","author":"Nagata","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2022031300131475100_B39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2022031300131475100_B40","doi-asserted-by":"crossref","first-page":"eaaf7779","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"2022031300131475100_B41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fimmu.2013.00113","article-title":"Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells","volume":"4","author":"Nikolic","year":"2013","journal-title":"Front Immunol"},{"key":"2022031300131475100_B42","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn\u2019s disease: a phase i study","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J Crohn\u2019s Colitis"},{"key":"2022031300131475100_B43","doi-asserted-by":"crossref","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022031300131475100_B44","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031300131475100_B45","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3389\/fimmu.2017.01598","article-title":"Translating mechanism of regulatory action of tolerogenic dendritic cells to monitoring endpoints in clinical trials","volume":"8","author":"Suwandi","year":"2017","journal-title":"Front Immunol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/dbi17-0043","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/67\/7\/1211\/525230\/dbi170043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/67\/7\/1211\/525230\/dbi170043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:35:50Z","timestamp":1667406950000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/67\/7\/1211\/35350\/Learning-From-Past-Failures-of-Oral-Insulin-Trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,6,15]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi17-0043","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]}}}